REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets
REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc
How this was made
The 30-second read
Why it matters
The deal expands Repligen's product portfolio and recurring revenue, likely supporting a share price rally, while BioLife will be absorbed.
Market read
First‑report of a material M&A transaction in the biotech sector; immediate price impact expected for RGEN.
What to watch
Regulatory approvals for combined product lines and potential antitrust scrutiny could delay synergies.
Background
Repligen (NASDAQ:RGEN) completed its previously announced acquisition of BioLife Solutions (NASDAQ:BLFS), a supplier of cell‑processing tools for gene‑therapy markets.
Ticker impact
Repligen announced completion of its acquisition of BioLife Solutions, receiving cash and stock, a material M&A event.
likely upward pressure as investors price in synergies and revenue expansion
The deal adds high‑margin consumables and broadens market reach; cash component and stock issuance are modest, suggesting accretive effect.
BioLife shareholders received cash and Repligen stock for their shares as part of the completed acquisition.
stock will be delisted; former shareholders benefit from cash and Repligen shares
The transaction ends BLFS as a standalone entity; price impact is limited to the transaction terms.
Market effects
Strengthens the bioprocessing and cell‑therapy supply chain, potentially boosting related equipment and consumable providers.
Adds to U.S. biotech M&A activity; modest impact on European peers.
Highlights growing demand for cell‑therapy manufacturing, may influence global biotech funding trends.
Counterpoint
If integration costs exceed expectations, the acquisition could dilute RGEN earnings and pressure the stock.
Key entities
- CompanyRepligen Corporation
Life‑sciences firm acquiring BioLife.
- CompanyBioLife Solutions, Inc.
Cell‑processing tools provider being acquired.
